You have been told your cancer is "rare." That your diagnosis appears in only a few cases per million. That your hospital has never seen it before. That there is no standard protocol.
In China, nothing is truly rare. With 1.4 billion people, a cancer that is "rare" in Europe or the US is routine here. A tumor type that a Western specialist sees once a career, our teams see monthly, sometimes weekly. At Fosun Health, we do not treat rare cancers as curiosities. We treat them as the core of our daily practice.
Surgery, chemotherapy, and radiation were invented for specific organs—but they do not belong to them. A radiofrequency probe that ablates a liver tumor also ablates a sarcoma in the thigh. A beam that tracks a lung nodule also tracks a recurrent salivary gland cancer in the skull base. An iodine-125 seed that irradiates a prostate bed also irradiates a chordoma in the sacrum. At Fosun Health, our cross-cancer technology platform treats the biology, not the organ name.
CyberKnife M6 delivers 0.1mm precision to any solid tumor, anywhere in the body. We do not ask "what kind of cancer is it?" We ask "where is it, and can we hit it without destroying what surrounds it?"
- Recurrent nasopharyngeal carcinoma in the skull base
- Lung metastases from renal cell carcinoma
- Bone metastases from melanoma
- Spinal epidural metastases causing paralysis risk
- Mediastinal recurrence after esophagectomy
- Unresectable pancreatic neuroendocrine tumor
All treated with the same principle: converge thousands of beams on the tumor. Spare everything else. All non-invasive. All 1–5 sessions.
Our interventional platform does not discriminate by organ. If a tumor has a blood supply, we can block it, poison it, or starve it. If it is accessible by needle, we can burn it, freeze it, or seed it with radiation.
Tool | What It Does | Rare Cancer Examples |
TACE / D-TACE / HAIC | Block arterial supply + deliver 50–100× local chemotherapy concentration | Hepatic metastases from neuroendocrine tumors (NETs); Gastrointestinal stromal tumor (GIST) liver deposits; Uveal melanoma liver metastases |
RFA / MWA / Cryoablation | Destroy tumor through a needle puncture, preserve healthy tissue | Osteoid osteoma (bone); Renal oncocytoma; Pulmonary carcinoid; Thyroid nodule ablation; Soft tissue sarcoma recurrence |
odine-125 Seeds | 60–180 days continuous internal radiation | Chordoma sacral recurrence; Salivary gland cancer perineural spread; Penile cancer lymph node metastasis |
Tumor Hyperthermia | 40–43°C sensitization for chemo/radiation | Malignant pleural mesothelioma; Desmoid tumor (aggressive fibromatosis); Any bulky tumor needing radiosensitization |
For cancers with no name—or cancers that have exhausted their named treatments—we turn to NGS and molecular profiling. We do not need to know where the cancer started. We need to know what drives it.
- NTRK fusion-positive solid tumors of ANY type: Larotrectinib or entrectinib—tumor-agnostic approved therapy.
- MSI-H / dMMR across all histologies: Pembrolizumab—approved for any solid tumor with this signature.
- BRAF V600E-mutated histiocytic neoplasms, sarcomas, or anaplastic thyroid cancer: Dabrafenib + trametinib.
- RET fusion-positive lung, thyroid, or salivary gland cancers: Selpercatinib or pralsetinib.
- IDH1-mutated cholangiocarcinoma or glioma: Ivosidenib.
When the label is rare, the target is what matters. And the target—plus the drug that hits it—is available here.
We do not list these to impress you with Latin names. We list them to show you: whatever you have, we have treated it before.
Cancer Type | What Makes It Rare | What We Do |
Soft Tissue Sarcoma (STS) | >70 subtypes; few surgeons outside major centers see more than a handful | Preoperative transarterial embolization shrinks the tumor for limb-sparing surgery; postoperative CyberKnife for positive margins; targeted therapy (pazopanib, larotrectinib) for metastatic disease |
Gastrointestinal Stromal Tumor (GIST) | KIT/PDGFRA-driven; imatinib-resistant mutations require second-line precision agents | Sunitinib, regorafenib, ripretinib sequencing; arterial embolization for liver metastases; ablation for small recurrences |
Neuroendocrine Tumors (NETs/NECs) | Often indolent but metastatic to liver; traditional chemotherapy ineffective for well-differentiated types | SSA (somatostatin analogues) + liver-directed TACE/HAIC + PRRT (lutetium-177) for advanced disease; surgery or ablation for limited metastases |
Uveal (Ocular) Melanoma | High rate of liver-only metastasis; no standard systemic therapy | Immunoembolization (via hepatic artery) + ipilimumab/nivolumab; CyberKnife for orbital recurrence; liver-directed therapies for metastatic control |
Head & Neck Salivary Gland Cancers | Diverse histology (adenoid cystic, mucoepidermoid, acinic cell); surgery risks facial nerve injury | Robotic/endoscopic resection with nerve monitoring; postoperative CyberKnife for perineural spread; iodine-125 seeds for skull-base recurrence |
Primary Unknown Cancer (CUP) | No identifiable origin; many hospitals refuse treatment | NGS "site-of-origin" profiling + molecular-matched therapy ( Pembrolizumab for MSI-H, larotrectinib for NTRK) + empirical platinum doublet with tumor hyperthermia radiosensitization |
Pediatric Solid Tumors | Require organ-sparing, fertility-preserving, growth-sparing approaches | Organ-sparing ablation for small renal tumors; CyberKnife for brain/spinal tumors avoiding craniotomy; fertility-preserving protocols with reduced-toxicity chemotherapy |
Desmoid Tumors (Aggressive Fibromatosis) | Locally invasive but non-metastasizing; traditional surgery often worsens recurrence | Tumor hyperthermia + low-dose chemotherapy (methotrexate/vinblastine) + cryoablation for painful lesions; imatinib or sorafenib for refractory cases |
For rare cancers, there is no standard playbook. So we write one—for you.
Every rare or complex case triggers an expanded MDT that may include:
- Pathology with sub-specialty expertise: A gastrointestinal pathologist who has seen 500 GISTs. A dermatopathologist who recognizes desmoplastic melanoma by sight. A bone pathologist who distinguishes chondrosarcoma from osteosarcoma in minutes.
- Molecular tumor board: Bioinformaticians and oncologists who interpret NGS reports not as lists of mutations, but as actionable drug maps.
- Interventional radiology: Mapping arterial anatomy for embolization, regardless of whether the tumor is in the liver, pelvis, or retroperitoneum.
- Radiation oncology: Designing IMRT, VMAT, or CyberKnife plans for anatomy that does not appear in standard textbooks.
- Surgical innovation: Robotic, endoscopic, or ablative approaches that avoid the "standard incision" when the standard incision would destroy function.
The MDT convenes within 48 hours. The plan is not a protocol downloaded from a guideline. It is a consensus blueprint built for your specific tumor biology, location, and life priorities.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
If you have been told your cancer is "too rare to treat," "has no standard protocol," or "requires travel to a distant research center"—upload your pathology report, imaging, and molecular profiling results. Our Rare and Complex Cancer MDT will review your case, identify the applicable technology platforms, and deliver a preliminary cross-disciplinary treatment plan within 48 hours.
There is no such thing as a tumor we have never seen.
